LONDON, March 21, 2014 /PRNewswire/ --
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day at 686.29, down 0.02%, while the same has gained 7.91% in the last three months. Investor-Edge has initiated coverage on the following equities: Dynavax Technologies Corp. (NASDAQ: DVAX), Forest Laboratories Inc. (NYSE: FRX), Orexigen Therapeutics Inc. (NASDAQ: OREX) and Endo International PLC (NASDAQ: ENDP). Free technical research on DVAX, FRX, OREX and ENDP can be downloaded upon signing up at:
Shares in Dynavax Technologies Corp. edged 0.53% higher to finish day at $1.88. A total of 1.40 million shares were traded, which is below the three months average volume of 4.69 million. The company's shares oscillated between $1.84 and $1.93 during the session. Dynavax Technologies Corp.'s shares have advanced 2.17% in the previous three trading sessions and 3.30% in the last one month, while the shares have declined 4.08% on YTD basis. The company's shares are trading above their 50-day and 200-day moving averages of $1.86 and $1.50, respectively. Moreover, the stock is trading at a Relative Strength Index (RSI) of 50.56. Sign up today to read free research on DVAX at:
On Thursday, shares in Forest Laboratories Inc. recorded a trading volume of 1.74 million shares, as compared with a three months average volume of 3.61 million shares. The stock ended the day at $95.69, down 0.32% and at an intraday range of $95.20 and $96.77. Shares of the company traded at a PE ratio of 121.40. Forest Laboratories Inc.'s shares have gained 0.46% in the previous three trading sessions and 59.40% on YTD basis, while the shares have fallen by 1.65% in the last one month. The company's shares are trading above their 50-day and 200-day moving averages of $80.12 and $54.79, respectively. Furthermore, the stock is trading at an RSI of 66.07. Sign up today to read free research on FRX at:
Shares in Orexigen Therapeutics Inc. gained 1.21%, closing the day at $7.53. The stock recorded trading volume of 1.54 million shares as compared to a three months average volume of 2.34 million shares. The stock fluctuated between $7.24 and $7.54 during the trading session. Orexigen Therapeutics Inc.'s shares have advanced 5.46% each in the previous three trading sessions and in the last one month. The company's shares have surged 33.75% on YTD basis. The company's stock is trading above its 50-day and 200-day moving averages of $6.82 and $6.34, respectively. Moreover, the stock is trading at an RSI of 61.39. Sign up today to read free research on OREX at:
Endo International PLC's shares recorded a trading volume of 1.94 million shares, as compared with a three months average volume of 2.32 million shares. The stock ended the day at $72.90, down 0.29% and recorded an intraday range of $72.70 and $73.83. Shares of the company traded at a PE ratio of 56.89. Endo International PLClc's shares have gained 1.60% in the previous three trading sessions and 8.06% on YTD basis, while the shares have declined 4.63% in the last one month. The company's stock is trading above its 50-day and 200-day moving averages of $71.57 and $53.59, respectively. Furthermore, the stock is trading at an RSI of 49.38. Sign up today to read free research on ENDP at:
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-edge. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Investor-edge in this article or report according to the Procedures outlined by Investor-edge. Investor-edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Investor-edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Investor-edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.